MAP2K7 and cancer: Initial results from clinical trials have not yielded overwhelming support for the use of MEK inhibitors as a single therapeutic agent in cancer patients who are not pre-screened for pre-existing activation of the Ras/Raf/MEK/ERK pathway [75,76,93].